Trinity Biotech Investor Presentation — December 2022

Document content

December 1, 2022Nasdaq: TRIBCorporate Presentation

Piper Sandler Healthcare

ConferenceDisclaimer

2This presentation includes statements that constitute “forward- looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including

but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth , market acceptance and penetration of new or planned product

offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe -harbor for forward -looking statements contained in the Reform Act.

These forward- looking statements are often characterised by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” o r words of similar import, and do not reflect historical facts.

Specific forward -looking statements contained in this presentation may be affected by risks and uncertainties, including, but no t limited to, the impact of the spread of COVID -19 and its

variants, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing

operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results , dependence on suppliers, the market acceptance of Trinity

Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a

commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks a ssociated with competing in the human diagnostic market, risks